open access
The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical Tomotherapy
open access
Abstract
Background/Aim
To examine the new dose-volume verification tool, called the two-component conformity index formula (TCCI), for tumours of the pituitary gland and tonsil cancer IMRT plans using helical Tomotherapy and a linear accelerator.
Material and Methods
10 medically inoperable patients – 5 with tumour of the pituitary gland and 5 tonsil cancers – were considered. Tomotherapy and Eclipse plans were compared by DVH analysis and new TCCI analysis including: 1/ the physician's intents for dose distribution in PRVs, 2/ more than one dose-volume constraint for dose distribution in PTV and healthy tissues, and 3/ separation between coverage and excess components.
Results
DVH analysis shows differences for the PTV received doses close to the prescription dose (PD): 1/in pituitary gland, Eclipse – 61% of PTV volume enclosed by PD and Tomotherapy – 50%, and 2/in tonsil cancer, Eclipse plans – 44% and Tomotherapy – 55%. These differences were clinically confirmed for tonsil cancer through TCCI analysis. Moreover, TCCI analysis shows better coverage of PTV volume through 90% and 95% isodose levels for Tomotherapy plans. Better high dose region reduction for brain stem and optic chiasm in pituitary gland and middle dose region reduction for parotids and spinal cord in tonsil and dose reduction in healthy tissues reported by TCCI analysis were observed for Tomotherapy plans.
Conclusions
The usefulness of the information provided means that TCCI could be used as a primary or alternative method of quick dose-volume verification finally supported by advanced DVH analysis.
Abstract
Background/Aim
To examine the new dose-volume verification tool, called the two-component conformity index formula (TCCI), for tumours of the pituitary gland and tonsil cancer IMRT plans using helical Tomotherapy and a linear accelerator.
Material and Methods
10 medically inoperable patients – 5 with tumour of the pituitary gland and 5 tonsil cancers – were considered. Tomotherapy and Eclipse plans were compared by DVH analysis and new TCCI analysis including: 1/ the physician's intents for dose distribution in PRVs, 2/ more than one dose-volume constraint for dose distribution in PTV and healthy tissues, and 3/ separation between coverage and excess components.
Results
DVH analysis shows differences for the PTV received doses close to the prescription dose (PD): 1/in pituitary gland, Eclipse – 61% of PTV volume enclosed by PD and Tomotherapy – 50%, and 2/in tonsil cancer, Eclipse plans – 44% and Tomotherapy – 55%. These differences were clinically confirmed for tonsil cancer through TCCI analysis. Moreover, TCCI analysis shows better coverage of PTV volume through 90% and 95% isodose levels for Tomotherapy plans. Better high dose region reduction for brain stem and optic chiasm in pituitary gland and middle dose region reduction for parotids and spinal cord in tonsil and dose reduction in healthy tissues reported by TCCI analysis were observed for Tomotherapy plans.
Conclusions
The usefulness of the information provided means that TCCI could be used as a primary or alternative method of quick dose-volume verification finally supported by advanced DVH analysis.
Keywords
Tomotherapy; IMRT; DVH; Conformity Index
About this articleTitle
The new two-component conformity index formula (TCCI) and dose-volume comparisons of the pituitary gland and tonsil cancer IMRT plans using a linear accelerator and helical Tomotherapy
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
133-145
Published online
2009-07-01
DOI
10.1016/S1507-1367(10)60028-4
Bibliographic record
Rep Pract Oncol Radiother 2009;14(4):133-145.
Keywords
Tomotherapy
IMRT
DVH
Conformity Index
Authors
Tomasz PIOTROWSKI
Piotr MARTENKA
Nathalie de PATOUL
Agata JODDA
Maxime COEVOET
Julian MALICKI
Stefaan VYNCKIER